| 667 | 6 | 81 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:探讨多种治疗方案对宫颈高危型人乳头瘤病毒(HPV)感染患者的临床治疗效果,为HPV患者的临床治疗提供新思路。方法:采用回顾性研究方法纳入2022年1月—2023年1月在宜昌市中心人民医院治疗的宫颈高危型HPV感染患者501例,根据患者选取的治疗方法分为三组,A组患者给予保妇康栓治疗(n=167),B组患者给予重组人干扰素α-2b凝胶治疗(n=167),C组给予抗HPV生物蛋白敷料治疗(n=167)。比较三组HPV患者治疗有效率、HPV-DNA水平、治疗后HPV阳性率和治疗过程中不良反应发生率,评价临床治疗效果。结果:C组患者治疗总有效率明显高于A组(90.42%vs 74.85%)和B组(90.42%vs 77.25%)(均P<0.05)。三组患者治疗3个月及6个月HPV-DNA水平较治疗前明显下降,且治疗3个月及6个月时,C组患者的HPV-DNA水平较A组和B组明显降低(均P<0.05)。治疗后C组HPV阳性率明显低于A组(6.60%vs 22.75%)和B组(6.60%vs 20.96%)(均P<0.05)。三组患者不良反应发生情况无明显统计学差异(P>0.05)。结论:抗HPV生物蛋白敷料对于宫颈高危型HPV感染患者的治疗效果优于保妇康栓及重组人干扰素α-2b凝胶,且不良反应发生少,值得临床上进一步推广。
Abstract:Objective: To explore the clinical therapeutic effect of multiple treatment methods on patients with high-risk cervical human papillomavirus(HPV) infection, and provide new ideas for clinical treatment of HPV patients. Methods: A total of 501 patients with high-risk cervical HPV infection treated in Yichang Central People's Hospital from January 2022 to January 2023 were included in this retrospective study, and they were divided into three groups according to the treatment methods. Patients in group A were treated with Baofu Kang suppository(n=167), patients in group B were treated with recombinant human interferon α-2b gel(n=167), and group C was treated with anti-HPV bioprotein dressing(n=167). The treatment effective rate, HPV-DNA level, HPV positive rate after treatment and the incidence of adverse reactions during treatment were compared among three groups.Results: The total effective rate in group C was significantly higher than that in group A(90.42% vs 74.85%) and group B(90.42% vs 77.25%)(both P<0.05). The HPV-DNA level in the three groups was significantly decreased at 3 and 6 months after treatment compared with that before treatment, and the HPV-DNA level in the C group was significantly reduced when compared to group A and group B(all P<0.05). After treatment, the HPV positive rate of group C was significantly lower than that of group A(6.60% vs 22.75%) and group B(6.60% vs 20.96%)(both P<0.05). There was no significant difference in the occurrence of adverse reactions among the three groups(P>0.05). Conclusion: The therapeutic effect of anti-HPV biological protein dressing on high-risk cervical HPV infection patients is better than Baofu Kang suppository and recombinant human interferon α-2b gel, which has few adverse reactions and is worthy of further promotion in clinic.
[1] Uwins C,Yilmaz Y,Bilir E,et al.World Gynecologic Oncology Day:the use of Twitter to raise awareness of gynecologic cancers[J].AJOG Glob Rep,2022,2(3):100079.
[2] 赵琛,宋淑芳.我国宫颈癌流行病学及病因学的研究[J].医学信息,2021,34(5):6-8.
[3] 唐宇星,王敏,张诗敏,等.不同药物对高危型HPV持续感染及宫颈癌前病变合并高危型HPV感染的临床疗效对比研究[J].实用药物与临床,2022,25(5):385-391.
[4] 吴涛,张瑞娜,刘倩男.女性HPV感染与宫颈癌前病变的相关性研究[J].实用癌症杂志,2023,38(1):42-45.
[5] 姜世勃,陆路.抗HPV生物蛋白基础研发及机制研究[C]//2013北京地区妇产科学术年会论文集,2013:21-24.
[6] 陈丹,张晓兰,周淑君.宫颈癌患者HPV-E6/E7mRNA HPV-DNA检测及临床意义[J].中国妇幼保健,2021,36(20):4808-4811.
[7] 李婵玉,邓洁,罗剑波.高危型HPV在宫颈癌发生发展中的作用机制[J].实用癌症杂志,2021,36(3):519-522.
[8] 陈香,董燕,张丽.宫颈高级别鳞状上皮内病变锥切术后高危型HPV持续感染的研究进展[J].实用医学杂志,2021,37(16):2039-2043.
[9] 蓝冬连,胡职青.重组人干扰素α-2b凝胶治疗慢性宫颈炎合并高危型HPV感染的效果[J].中外医学研究,2021,19(6):47-50.
[10] Guo X T,Qiu L X,Wang Y H,et al.Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally[J].J Med Virol,2016,88(6):1098-1101.
[11] 莫子茵,陈荃,代歆悦,等.HPV致癌与氧化应激的协同作用及Nrf2信号通路的研究进展[J].中国艾滋病性病,2018,24(1):105-107.
[12] 黄永萍,莫锐婷.抗HPV生物蛋白敷料与重组人干扰素α-2b凝胶治疗宫颈高危型HPV持续感染患者的临床效果[J].临床医学工程,2022,29(8):1087-1088.
[13] 陈莹,王彤彤,王虹.抗HPV生物蛋白敷料治疗宫颈高危型HPV感染的临床疗效[J].中国社区医师,2016,32(26):77-78.
[14] 张媛,糜媛媛,谢绮,等.LEEP联合干扰素和抗HPV生物蛋白敷料治疗HSIL伴高危型人乳头瘤病毒感染效果[J].中国计划生育学杂志,2022,30(4):761-764.
[15] 明小琼,陈莉莉.抗HPV生物蛋白敷料联合保妇康栓治疗宫颈糜烂合并高危型HPV感染的效果及对阴道微生态和炎症因子的影响[J].中外医学研究,2022,20(30):48-52.
[16] 何晶,张烽,朱佳尔.抗HPV生物蛋白敷料与重组人干扰素α-2b凝胶治疗高危型HPV感染的研究[J].中华医院感染学杂志,2020,30(3):403-408.
基本信息:
中图分类号:R737.33
引用信息:
[1]朱弘宇,冯祥,罗幼珍.不同治疗方案对宫颈高危型HPV感染患者的治疗效果分析[J].巴楚医学,2024,7(01):50-54.
基金信息:
重大疾病共性机制研究全国重点实验室开放研究课题《铁螯合剂治疗PTEN缺失的子宫内膜癌》
2024-03-27
2024-03-27